Details for Patent: 10,912,751
✉ Email this page to a colleague
Which drugs does patent 10,912,751 protect, and when does it expire?
Patent 10,912,751 protects NEXLIZET and is included in one NDA.
This patent has twenty-seven patent family members in sixteen countries.
Summary for Patent: 10,912,751
| Title: | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| Abstract: | Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject. |
| Inventor(s): | Newton; Roger Schofield (Ann Arbor, MI), Rosenberg; Noah Laban (Livingston, NJ), MacDougall; Diane Elaine (Lincoln, MA) |
| Assignee: | Esperion Therapeutics, Inc. (Ann Arbor, MI) |
| Application Number: | 15/558,084 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Dosage form; |
Drugs Protected by US Patent 10,912,751
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF LOWERING LDL-C OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING A FIXED-DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE | ⤷ Sign Up | ||||
| Esperion Theraps Inc | NEXLIZET | bempedoic acid; ezetimibe | TABLET;ORAL | 211617-001 | Feb 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,912,751
| PCT Information | |||
| PCT Filed | March 14, 2016 | PCT Application Number: | PCT/US2016/022319 |
| PCT Publication Date: | September 22, 2016 | PCT Publication Number: | WO2016/149191 |
International Family Members for US Patent 10,912,751
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016233485 | ⤷ Sign Up | |||
| Australia | 2021218120 | ⤷ Sign Up | |||
| Australia | 2024202106 | ⤷ Sign Up | |||
| Brazil | 112017019358 | ⤷ Sign Up | |||
| Canada | 2978204 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
